Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
148.5 USD | -0.68% | +2.60% | -5.24% |
Apr. 24 | Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset | DJ |
Apr. 24 | Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study | MT |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an enterprise value anticipated at 3.97 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.24% | 358B | C+ | ||
+25.61% | 660B | C+ | ||
+23.49% | 562B | B | ||
+16.49% | 322B | B- | ||
+8.28% | 297B | C+ | ||
+13.00% | 219B | B+ | ||
-9.61% | 196B | A+ | ||
+6.68% | 199B | B- | ||
-8.75% | 149B | C+ | ||
-5.21% | 146B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- Ratings Johnson & Johnson